A Neutralizing Antibody-Conjugated Photothermal Nanoparticle Captures and Inactivates SARS-CoV-2
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
The outbreak of 2019 coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in a global pandemic. Despite intensive research including several clinical trials, currently there are no completely safe or effective therapeutics to cure the disease. Here we report a strategy incorporating neutralizing antibodies conjugated on the surface of a photothermal nanoparticle to actively capture and inactivate SARS-CoV-2. The photothermal nanoparticle is comprised of a semiconducting polymer core and a biocompatible polyethylene glycol surface decorated with neutralizing antibodies. Such nanoparticles displayed efficient capture of SARS-CoV-2 pseudoviruses, excellent photothermal effect, and complete inhibition of viral entry into ACE2-expressing host cells via simultaneous blocking and inactivating of the virus. This photothermal nanoparticle is a flexible platform that can be readily adapted to other SARS-CoV-2 antibodies and extended to novel therapeutic proteins, thus providing a broad range of protection against multiple strains of SARS-CoV-2.
Article activity feed
-
SciScore for 10.1101/2020.11.30.404624: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Anti-SARS-CoV-2 neutralizing antibodies were added into the nanoparticle solution with a mass ratio of 1:10 (antibody: DSPE-PEG2000-NHS) and stirred overnight at 4 °C to complete the conjugation. Anti-SARS-CoV-2 neutralizingsuggested: NoneFluorescent Imaging of Photothermal Nanoparticles: The photothermal nanoparticles (100 μg/mL, 10 μL) was incubated with the secondary Alexa Fluor 488-labeled anti-IgG2b antibody (100 μg/mL, 10 μL) for 1 h. anti-IgG2bsuggest…SciScore for 10.1101/2020.11.30.404624: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Anti-SARS-CoV-2 neutralizing antibodies were added into the nanoparticle solution with a mass ratio of 1:10 (antibody: DSPE-PEG2000-NHS) and stirred overnight at 4 °C to complete the conjugation. Anti-SARS-CoV-2 neutralizingsuggested: NoneFluorescent Imaging of Photothermal Nanoparticles: The photothermal nanoparticles (100 μg/mL, 10 μL) was incubated with the secondary Alexa Fluor 488-labeled anti-IgG2b antibody (100 μg/mL, 10 μL) for 1 h. anti-IgG2bsuggested: NoneExperimental Models: Cell Lines Sentences Resources In Vitro Viral Infection of SARS-CoV-2 VSV-GFP Pseudovirus: ACE2/HEK293T cells (5 × 104 cells) were seeded into 96-well plates (flat bottom, GenClone®) and incubated overnight at 37 °C in a humified CO2 incubator. ACE2/HEK293Tsuggested: NoneSoftware and Algorithms Sentences Resources The numbers of total cells and infected cells were counted in ImageJ using the following workflow: Adjust→Threshold (Otsu), Process→Binary→Fill Holes→Watershed, Analyze→ Analyze Particles. ImageJsuggested: (ImageJ, RRID:SCR_003070)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-